Director/PDMR Shareholding

GW Pharmaceuticals PLC Director/PDMR Shareholding

22 December 2015

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Cambridge, UK, 22 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the following transaction in the 0.1 pence ordinary shares of the Company has taken place today.

Adam George, a Director and Chief Financial Officer of the Company, has today acquired 2,065 0.1 pence ordinary shares of GW Pharmaceuticals plc (equivalent to 172 American Depositary Shares, or ADSs) from the GW employee benefit trust operated by GWP Trustee Company Ltd. These shares were originally conditionally gifted to Mr George in November 2008 under the terms of the GW Pharmaceuticals All Employee Share Ownership Plan. Mr George has today elected to transfer the shares out of the ownership of the employee benefit trust into his personal shareholding. The transfer took place when the market price of the shares was 366 pence per share.

In addition, Mr George has today elected to exercise options granted to him under the GW Long term incentive Plan 2008 to acquire 3,856 0.1 pence ordinary shares. The average exercise price was 0.1 pence per share and the market price at the time of exercise was 366 pence per share.

Mr George has elected to retain these shares.

Following these acquisitions of shares, Mr George's total beneficial interest in the 0.1 pence ordinary shares of GW Pharmaceuticals plc has increased by 5,921 shares to 27,617 0.1 pence ordinary shares (equivalent to 2,301 ADSs), representing less than 0.1% of the Company's current issued share capital.

The total number of shares outstanding in the Company is 262,577,877 ordinary shares of 0.1 pence each.

For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser)

James Steel +44 (0) 20 7418 8900